Search results
Results from the Tech24 Deals Content Network
This product information is intended only for residents of the United States. for Healthcare professionals: Visit www.eliquis.com for U.S. Physician Prescribing Information. Investors.
In 2015, Bristol Myers Squibb provided more than $694 million in free medicines to more than 65,000 US patients. Learn more about qualifying for help paying for medications.
See Important Safety Info, including Boxed WARNINGS. Request ELIQUIS® samples and get resources for HCPs & Patients, including savings offers & starter guides.
Apixaban, sold under the brand name Eliquis, is an anticoagulant medication used to treat and prevent blood clots and to prevent stroke in people with nonvalvular atrial fibrillation through directly inhibiting factor Xa. [6][7][8] It is used an alternative to warfarin to prevent blood clots following hip or knee replacement and in those with a ...
The FDA granted approval of the generic apixaban applications to Micro Labs Limited and Mylan Pharmaceuticals Inc. Please contact the manufacturers for information about the medicine’s...
ELIQUIS is the only oral anticoagulant to demonstrate superior risk reductions versus warfarin in three key outcomes—stroke and systemic embolism, major bleeding, and all-cause mortality—for patients with nonvalvular atrial fibrillation.
Given today’s decision, the earliest that generic manufacturers are permitted to launch their apixaban products is April 1, 2028, subject to additional appeals and challenges.
Generic drug availability, manufacturer information, and patent status on Eliquis
Eliquis (apixaban) is used to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. Includes Eliquis side effects, interactions and indications.
FDA approval history for Eliquis (apixaban) used to treat Prevention of Thromboembolism in Atrial Fibrillation, Deep Vein Thrombosis Prophylaxis after Knee Replacement Surgery, Deep Vein Thrombosis Prophylaxis after Hip Replacement Surgery. Supplied by Bristol-Myers Squibb Company and Pfizer Inc.